Trial site
Nara Medical University Hospital
Kashihara-shi, Nara 634-8522, JapanNot linked to an institution yet
The trials here
What the 7 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 21 trial
- Status
- Recruiting5 trials
- Active, not recruiting2 trials
- Lead sponsor
- Hoffmann-La Roche2 trials
- Janssen Research & Development, LLC2 trials
- Astellas Pharma Global Development, Inc.1 trial
- Revolution Medicines, Inc.1 trial
- Takeda1 trial
Running trials
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT07416526· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Contact: Kazuhiko Tsuruya (principal investigator)
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error